Analyzing VYNE Therapeutics (NASDAQ:VYNE) and OmniAb (NASDAQ:OABI)

VYNE Therapeutics (NASDAQ:VYNE) and OmniAb (NASDAQ:OABI) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, dividends and earnings.

Earnings & Valuation

This table compares VYNE Therapeutics and OmniAb”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
VYNE Therapeutics	$454,000.00	50.16	-$26.48 million	($0.38)	-1.80
OmniAb	$18.67 million	20.24	-$64.78 million	($0.46)	-5.67

VYNE Therapeutics has higher earnings, but lower revenue than OmniAb. OmniAb is trading at a lower price-to-earnings ratio than VYNE Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares VYNE Therapeutics and OmniAb’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
VYNE Therapeutics	-4,726.21%	-70.42%	-63.46%
OmniAb	-187.59%	-20.31%	-18.10%

Volatility & Risk

VYNE Therapeutics has a beta of 2, indicating that its share price is 100% more volatile than the S&P 500. Comparatively, OmniAb has a beta of 0.41, indicating that its share price is 59% less volatile than the S&P 500.

Analyst Ratings

This is a summary of recent recommendations for VYNE Therapeutics and OmniAb, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
VYNE Therapeutics	1	3	0	0	1.75
OmniAb	1	0	2	0	2.33

OmniAb has a consensus target price of $3.00, suggesting a potential upside of 14.94%. Given OmniAb’s stronger consensus rating and higher probable upside, analysts plainly believe OmniAb is more favorable than VYNE Therapeutics.

Insider and Institutional Ownership

83.8% of VYNE Therapeutics shares are owned by institutional investors. Comparatively, 72.1% of OmniAb shares are owned by institutional investors. 3.0% of VYNE Therapeutics shares are owned by insiders. Comparatively, 9.8% of OmniAb shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

OmniAb beats VYNE Therapeutics on 8 of the 14 factors compared between the two stocks.

About VYNE Therapeutics

VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan- bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure. It also develops VYN202, a BD2-selective oral small molecule BET inhibitor for the treatment of immuno-inflammatory indications. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.

About OmniAb

OmniAb, Inc., a biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States. The company's technology platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts. Its OmniAb platform is the biological intelligence of proprietary transgenic animals, including OmniRat, OmniChicken, and OmniMouse that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. The company's OmniFlic, a bispecific rat, and OmniClic, a bispecific chicken, designed for discovery of bispecific antibody applications; OmniTaur, which provides unique structural characteristics of cow antibodies for complex targets; and OmniDeep, a suite of in silico, an AI and machine learning tools for therapeutic discovery and optimization through various technologies and capabilities. OmniAb, Inc. was founded in 2012 and is headquartered in Emeryville, California.